Analyst Ratings For NASDAQ:LOXO – Loxo Oncology (NASDAQ:LOXO)
Today, Citigroup raised its price target on NASDAQ:LOXO – Loxo Oncology (NASDAQ:LOXO) to per share.
Some recent analyst ratings include
- 5/17/2018-BTIG Research Reiterated Rating of Buy.
- 4/16/2018-Morgan Stanley Upgrade from a “Equal Weight ➝ Overweight” rating to a “” rating.
- 4/16/2018-William Blair Reiterated Rating of Buy.
- 3/1/2018-Cann Reiterated Rating of Buy.
- On 5/15/2018 Joshua H Bilenker, CEO, sold 15,000 with an average share price of $136.51 per share and the total transaction amounting to $2,047,650.00.
- On 5/15/2018 Naarden Jacob Van, Insider, sold 3,082 with an average share price of $137.42 per share and the total transaction amounting to $423,528.44.
- On 4/25/2018 Joshua H Bilenker, CEO, sold 15,000 with an average share price of $131.12 per share and the total transaction amounting to $1,966,800.00.
- On 4/25/2018 Naarden Jacob Van, Insider, sold 3,082 with an average share price of $131.23 per share and the total transaction amounting to $404,450.86.
- On 4/24/2018 Jennifer Burstein, VP, sold 1,700 with an average share price of $131.65 per share and the total transaction amounting to $223,805.00.
- On 4/20/2018 Lori Anne Kunkel, Director, sold 5,000 with an average share price of $132.68 per share and the total transaction amounting to $663,400.00.
- On 3/14/2018 Joshua H Bilenker, CEO, sold 15,000 with an average share price of $131.54 per share and the total transaction amounting to $1,973,100.00.
Recent Trading Activity for NASDAQ:LOXO – Loxo Oncology (NASDAQ:LOXO)
Shares of NASDAQ:LOXO – Loxo Oncology closed the previous trading session at 166.29 down -1.24 0.74% with shares trading hands.